With over 30 years' expertise in developing and manufacturing treatments for inflammatory bowel disease, Tillotts Pharma UK are dedicated to supporting healthcare professionals and improving patient care.
A Brexit message from Jeremy Thorpe, Managing Director of Tillotts Pharma UK
Latest news
Tillotts Pharma UK are platinum sponsors of BSG Campus 2021
Tillotts Pharma UK are proud to be platinum sponsors of the first virtual BSG Campus, held between 21st and 29th […]
Tillotts Pharma UK gold sponsors of GIN 2021
Tillotts Pharma UK are proud to be gold sponsors of the 8th National Gastrointestinal Nursing Conference The conference will be […]
Brexit and the supply of Medicines for Northern Ireland
How Tillotts have changed our supply arrangements for Northern Ireland following the end of the Brexit Transitional period
Find out moreTillotts in the UK
Tillotts Pharma AG has a strong presence in Europe with affiliates and distributors in all major European markets. The UK business is the largest wholly owned affiliate of Switzerland based Tillotts Pharma AG, and part of the Japanese Zeria Group.
Tillotts Pharma UK Ltd was established in March 2010. Jeremy Thorpe (Managing Director) joined in July 2012, with a clear focus on optimising the portfolio of gastrointestinal (GI) health products. Tillotts Pharma UK is now a market leader.
GI health
Improving care for people with GI diseases
Since its foundation, Tillotts has been committed to improving care for people with gastrointestinal (GI) diseases. We collaborate with healthcare professionals and GI-experts to develop and market medicines for the treatment of diseases of the digestive system.
Our specific focus on the digestive system means we have in-depth knowledge of the challenges that gastroenterologists and hepatologists face on a daily basis. It also helps us look for innovative ways to improve care and quality of life for the 5–6 million people who live with inflammatory bowel diseases worldwide.
Inflammatory Bowel Disease (IBD)
IBD is a group of chronic conditions in which the body’s immune system attacks part of the digestive system. These condi [...]
Read more
»
Ulcerative Colitis (UC)
Ulcerative colitis involves chronic inflammation of the lining of the large intestine. Unlike Crohn’s disease, which can [...]
Read more
»
Crohn’s Disease (CD)
Crohn’s disease is caused by chronic inflammation of the digestive tract. Symptoms vary, but often include abdominal pai [...]
Read more
»
Microscopic Colitis (MC)
Like ulcerative colitis (UC), microscopic colitis affects the colon and rectum, however the inflammation of the intestin [...]
Read more
»
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Tillotts Pharma UK Ltd on 01522 813500 or uksafety@tillotts.com
Close window
NU-00984 January 2021